kaolinite and Liver-Cirrhosis

kaolinite has been researched along with Liver-Cirrhosis* in 4 studies

Other Studies

4 other study(ies) available for kaolinite and Liver-Cirrhosis

ArticleYear
A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2008, Volume: 19, Issue:6

    Thromboelastography can be performed with native or citrated blood (a surrogate to native blood in healthy controls, surgical and cirrhotic patients). Activators such as kaolin are increasingly used to reduce the time to trace generation. To compare kaolin-activated thromboelastography with nonkaolin-activated thromboelastography of native and citrated blood in patients with liver disease, patients undergoing treatment with warfarin or low-molecular weight heparin and healthy volunteers. We studied thromboelastography parameters in 21 healthy volunteers (group 1) and 50 patients, including 20 patients with liver cirrhosis with a nonbiliary aetiology (group 2), 10 patients with primary biliary cirrhosis or primary sclerosing cholangitis (group 3), 10 patients on warfarin treatment (group 4) and 10 patients with enoxaparin prophylaxis (group 5). Thromboelastography was performed using four methods: native blood (kaolin-activated and nonkaolin-activated) and citrated blood (kaolin-activated and nonkaolin-activated). For all thromboelastography parameters, correlation was poor (Spearman correlation coefficient < 0.70) between nonkaolin-activated and kaolin-activated thromboelastography, for both citrated and native blood. In healthy volunteers, in patients with liver disease and in those receiving anticoagulant treatment, there was a poor correlation between nonkaolin-activated and kaolin-activated thromboelastography. Kaolin-activated thromboelastography needs further validation before routine clinical use in these settings, and the specific methodology must be considered in comparing published studies.

    Topics: Adult; Aged; Anticoagulants; Artifacts; Blood Specimen Collection; Cholangitis, Sclerosing; Citrates; Enoxaparin; False Positive Reactions; Female; Hepatitis, Viral, Human; Humans; International Normalized Ratio; Kaolin; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Diseases; Male; Middle Aged; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sodium Citrate; Thrombelastography; Warfarin

2008
Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants.
    Thrombosis research, 1992, Aug-15, Volume: 67, Issue:4

    We have developed a Silica Clotting Time (SCT) test suitable to screen patients with lupus anticoagulants (LA) and compatible with photo-optical instruments. The SCT results were considered to be positive for LA whenever the clotting times were longer than the upper normal limit at low phospholipid concentration and to be confirmed when the prolonged clotting times were corrected to normal by high phospholipid concentration. We studied plasmas from healthy subjects, patients with known diagnoses of LA, patients with acquired deficiencies of blood coagulation and hemophiliacs with anti-factor VIII antibodies. The test was positive for all LA patients, and negative for all non-LA patients except 7 hemophiliacs with anti-factor VIII antibodies. Our data indicate that the SCT is a sensitive test, suitable for screening patients suspected of having LA. Its compatibility with photo-optical instruments makes it a suitable candidate to replace the kaolin clotting time. The contemporaneous performance of SCT at low and high phospholipid concentrations provides screening and confirmation in a single procedure.

    Topics: Anticoagulants; Autoantibodies; Blood Coagulation Disorders; Blood Coagulation Tests; Factor VIII; Hemophilia A; Humans; Kaolin; Liver Cirrhosis; Lupus Coagulation Inhibitor; Mass Screening; Phospholipids; Sensitivity and Specificity; Silicon Dioxide

1992
Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.
    Advances in experimental medicine and biology, 1976, Volume: 70, Issue:00

    Plasma prekallikrein (kallikreinogen) and kallikrein inhibitor, assayed with the kaolin activable esterase method, have been evaluated in 20 patients with hepatic cirrhosis, in 12 cases with jaundice from acute viral hepatitis, and in 9 normal. A significant reduction of the plasma prekallikrein in cirrhosis has been found. A lowering of plasma prekallikrein has also been observed in viral hepatitis; in this condition, however, the modifications were less important than those obtained in cirrhosis. In three cases of hepatitis, the behaviour of the plasma prekallikrein and kallikrein inhibitor have been controlled during the period of the disease and compared with the behaviour of some conventional parameters, such as serum transaminases and bilirubin. An important increase of the prekallikrein level has been observed during the improvement of hepatitis. These data confirm the implication of the prekallikrein-kallikrein system in severe liver diseases, and indirectly points out the role of the liver in maintaining the physiological balance of the kallikrein system.

    Topics: Adult; Aged; Aprotinin; Arginine; Enzyme Activation; Hepatitis A; Humans; Kallikreins; Kaolin; Liver Cirrhosis; Middle Aged; Prekallikrein

1976
Observations on the plasma kallikreinogen (prekallikrein)-kallikrein enzyme system.
    Transactions of the Association of American Physicians, 1968, Volume: 81

    Topics: Acids; Alcoholism; Angioedema; Aprotinin; Arginine; Bradykinin; Carcinoid Tumor; Chemical Phenomena; Chemistry; Esterases; Esters; Factor XII; Humans; Kallikreins; Kaolin; Liver Cirrhosis; Methane

1968